Meet the biopharma CEO who’s bullish on psychedelic-assisted therapies

Just over two years ago, the FDA issued its first draft guidance on clinical trials with psychedelic drugs. Now, HHS has hired a dedicated psychedelics advisor. 

This week, Reunion Neuroscience reported a mid-stage success with its short-acting psychedelic drug in postpartum depression.

At a moment of increasing momentum – both in terms of research, funding and commercial promise – behind psychedelics, it’s worth checking in with one of the leaders in the space: Cybin, a clinical-stage biopharma.

In November, Cybin reported positive Phase 2 data for its major depressive disorder drug and has its sights set on next steps in the regulatory approval process.

Pharma Editor Lecia Bushak brings us a conversation with Cybin CEO Doug Drysdale about "second-generation" psychedelics and how they are impacting the mental health treatment space.

For our Trends segment, we’re talking about recent updates to health data sharing on the federal level.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: Opal 99 - Can't Go Out and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.